Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Autonomic Neuropathy Treatment & Management

  • Author: Steven D Arbogast, DO; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: May 05, 2016
 

Medical Care

General management

The first objective of management of a patient with autonomic neuropathy is to administer specific treatment for treatable conditions. For example, if an autoimmune neuropathy is present, attempted management with immunomodulatory therapies should be considered. If diabetes mellitus is the underlying cause, strict control of blood glucose to prevent further worsening is essential. However, many of the autonomic neuropathies are not treatable with specific therapy. In these cases, symptomatic therapy becomes vitally important.

In cases of orthostatic intolerance, conservative therapy should be attempted first. Maintenance of high intakes of fluid and salt, as tolerated, can be attempted. The action of simply drinking 1-2 glasses of water can have a significant effect on systolic blood pressure. In patients with severe neurogenic orthostatic hypotension, intake of this volume led to an increase in systolic blood pressure of more than 30 mm Hg.[68] Plasma norepinephrine in this patient group increased, and this vasopressor response was almost completely abolished by intravenous ganglion blockade. Therefore, simply drinking water increases blood pressure not only by increasing volume status, but also by increasing sympathetic activity.

Avoidance of alcohol, which could lead to a delayed hypovolemic state, as well as a second cause of autonomic neuropathy, should be advised. Slow cautious movements between different body postures should be emphasized.

Encourage patients to sit or lie down upon the initiation of orthostatic symptoms. The head of the bed can be elevated so the patient sleeps at a 15-20° angle to stimulate nocturnal mineralocorticoid release. Physical counter-maneuvers should also be attempted.[69] The maneuvers include crossing the legs, squatting, and tensing the leg muscles, abdominal muscle, buttocks, or whole body.

Compressive stockings should be used. The thigh-high moderate compression stockings give the most benefit. Although they are difficult to put on and can be uncomfortable for patients, they should be strongly encouraged to use these as much as possible.

Gentle isometric exercises to help build up muscle tone is essential for patients with orthostatic intolerance. We often time recommend water aerobics or water jogging. If a place to perform these types of exercises is not available, then patients are encouraged to start gentle aerobic exercises often times with a recumbent bicycle, to avoid putting them in a position where they may experience loss of consciousness or fall.

Conservative treatment for other symptoms may also be tried, including eating smaller frequent meals, artificial tears for dry eyes, antiperspirants for hyperhidrosis and avoidance of hot environments for patients with anhidrosis.

Pharmacologic therapy

Pharmacologic therapy of orthostatic intolerance should be attempted in more difficult cases or when conservative therapy is unsuccessful.

Several medications are effective in controlling orthostatic intolerance. In less severe cases, such as in patients with POTS, medications such as beta-blockers for controlling heart rate may be sufficient.[70] In more severe cases, volume expansion with fludrocortisone[71] or venoconstriction with the α 2-adrenergic agonist midodrine[72] may be necessary. Remembering that both of these medications may lead to supine hypertension is important and a balance may be difficult to strike. Pyridostigmine has been used successfully for treatment of both POTS and orthostatic hypotension.[73] In addition, selective serotonin reuptake inhibitors (SSRIs)[74] and phenobarbital[75] have been shown to benefit specific patients.

Erythropoietin therapy can be effective in treating orthostatic hypotension in some patients, particularly patients with diabetes who have anemia and orthostatic hypotension.[76] Erythropoietin may increase norepinephrine levels, thereby improving vasomotor tone. Also, erythropoietin promotes increased vascular sensitivity to angiotensin II, possibly through nitric oxide, and it may have direct pressor effects on vascular smooth muscle cells. DDAVP (vasopressin) produces an antidiuretic function at the renal tubuli, preventing nocturesis and elevating morning blood pressure.[77]

If an autoimmune cause of the autonomic neuropathy is found or strongly suspected, then immunomodulatory therapy may be considered. Intravenous immunoglobulin (IVIG)[78] plasmapheresis[79] and oral immunosuppressant medications[80] have been used successfully.

Possible management for gastrointestinal autonomic neuropathy in patients with diabetes may include aminoguanidine, which can prevent diabetes-induced changes in nitric oxide synthase–related changes in animal models of ileum autonomic neuropathy.[81]

Next

Treatments for Specific Conditions

Treatment of specific conditions can be tailored to the particular disease or syndrome .

Urogenital dysfunction

Bladder dysfunction should be investigated with a urodynamic study initially before therapies are introduced.

Conservative therapy may be sufficient in mild dysfunction, such as a strict fluid schedule and bladder training. In cases of spastic bladder activity, medications such as tolterodine and oxybutynin may be useful. In cases of detrusor areflexia, cholinergic medications such as bethanechol may be helpful.

Refractory situations may require intermittent catheterization. Surgical options such as artificial sphincters may be necessary in some patients.

Sexual dysfunction may require treatment with agents such as sildenafil, tadalafil, or vardenafil. The efficacy and safety of these agents in patients with diabetes who have autonomic failure and orthostatic hypotension is largely unknown. Less commonly, prosthetic or assistive devices may be required.

Gastrointestinal conditions

Gastrointestinal difficulties can be present in many autonomic neuropathies, and may not be recognized by either the patient or the physician as symptomatic of autonomic dysfunction.

Changes in diet, small frequent meals, increased fiber ingestion, and increased fluid intake can be attempted first. In patients with Sj ö gren syndrome or thyroiditis, problems with hyposalivation can lead to difficulties in oral hygiene, and the patient should be reminded about regular dental checkups. Over-the-counter saliva replacements may be tried. Pyridostigmine can increase saliva output. Occasionally, cyproheptadine can be useful in treatment of altered sense of taste.

Pandysautonomia

The treatment of pandysautonomia is mainly supportive until spontaneous recovery can occur. In some patients, orthostatic hypotension may be relieved by fludrocortisone 0.1-0.2 mg daily or midodrine hydrochloride at 5-15 mg daily. Erythropoietin may be helpful in some patients with orthostatic hypotension.[76] No definite evidence of course-modifying treatment exists, although glucocorticoid therapy, plasma exchange, and IVIG therapy have all been attempted. Most patients have a good prognosis once the acute episode is over.

Postural orthostatic tachycardia syndrome

The treatment of POTS may require a high-salt diet and high fluid intake. Beta-adrenergic agonists, pyridostigmine, midodrine, fludrocortisone, SSRIs and erythropoietin may be useful in some patients.[82]

Dysautonomia

Management of dysautonomia in cases of GBS is difficult.[39, 40] Primary therapy of the condition consists of supportive measures and IVIG or plasma exchange therapy. Vasoactive therapy is occasionally required and should be administered in an intensive care unit with intra-arterial blood pressure monitoring. Patients with severe bradyarrhythmias can require pacemaker assessment.

Lambert-Eaton myasthenic syndrome

The treatment of LEMS involves treatment of underlying malignancy in appropriate cases. The use of immunosuppressive therapies such as prednisone, azathioprine, plasma exchange, and IVIG has also been successful. Autonomic dysfunction in LEMS may also respond to 3,4 diaminopyridine, which may also lead to improvements in strength.

Amyloidoses

In amyloidoses associated with myeloma, treatment must be directed against the myeloma.

Sj ö gren syndrome

Sj ö gren syndrome is probably autoimmune. Although a trial may be indicated in particular patients, responses to immunosuppression are largely unsatisfying. Symptoms of xerophthalmia may be treated with artificial tears.

Hypohidrosis or hyperhidrosis

Patients who have lack of sweat output need to be educated about the risk of heat intolerance. They should be encouraged to avoid excessive and prolonged heat exposure as they may have poor thermoregulation and be at risk for heat stroke.

For patients who have increased sweat output, several medication choices may be of benefit. Botulinum toxin has been used for focal hyperhidrosis.[83] If patient's symptoms are more generalized, medications with anticholinergic action or side effects may be tried. These include amitriptyline, glycopyrrolate, scopolamine patch, and hyoscyamine and belladonna tincture.

Porphyria

Porphyria can be treated by intravenous infusion of hematin, glucose, and vitamin B 6 .

Previous
Next

Surgical Care

Liver transplant should be considered for patients with FAP that is associated with a transthyretin defect. Transthyretin is a serum transport protein synthesized primarily in the liver, and transplantation prevents its production in the abnormal form and thus prevents its deposition.[84, 85]

Liver transplant may also be considered in patients with other hepatic disease related neuropathies. The neuropathies may be reversible in particular cases.

Uremic neuropathy with autonomic dysfunction has shown some reversibility with renal transplantation, whereas dialysis does not appear to improve the autonomic deficit.

Previous
Next

Consultations

Consultations should be considered based upon the underlying pathophysiology of the autonomic neuropathy.

Infectious conditions, such as HIV infection, Chagas disease, leprosy, diphtheria, and Lyme disease may require the input of an infectious diseases expert.

Consultations with internal medicine specialists, including endocrinologists, hepatologists, and nephrologists, are often useful in the diagnosis and management of forms of amyloidosis, porphyria, diabetes mellitus, thyroiditis, hepatic failure, and renal failure.

A rheumatologist can be of great assistance in diagnosing and managing cases of Sj ö gren syndrome, rheumatoid arthritis, systemic lupus erythematosus, and other connective tissue disorders.

Previous
Next

Diet

The treatment of patients with orthostatic intolerance may require a high-salt diet and high fluid intake as noted above.

Previous
 
 
Contributor Information and Disclosures
Author

Steven D Arbogast, DO Fellow, Neuromuscular Medicine, University Hospitals Case Medical Center, Cleveland

Steven D Arbogast, DO is a member of the following medical societies: American Academy of Neurology, American Osteopathic Association

Disclosure: Nothing to disclose.

Coauthor(s)

Bashar Katirji, MD, FACP Director, Neuromuscular Center and EMG Laboratory, The Neurological Institute, University Hospitals Case Medical Center; Professor of Neurology, Case Western Reserve University School of Medicine

Bashar Katirji, MD, FACP is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Physicians, American Neurological Association

Disclosure: Nothing to disclose.

J Douglas Miles, MD, PhD Assistant Professor of Neuroscience, Marshall University School of Medicine, and Clinical Instructor of Neurology, Case Western Reserve University School of Medicine

J Douglas Miles, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Medical Association, Society for Neuroscience

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Paul E Barkhaus, MD Professor of Neurology and Physical Medicine and Rehabilitation, Department of Neurology, Medical College of Wisconsin; Section Chief, Neuromuscular and Autonomic Disorders, Department of Neurology, Director, ALS Program, Medical College of Wisconsin

Paul E Barkhaus, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

References
  1. Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore). 2006. 85(4):229-238. [Medline].

  2. Davidson GL, Murphy SM, Polke JM, Laura M, Salih MA, Muntoni F, et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol. 2012 Feb 1. [Medline].

  3. Bejaoui K, Wu C, Scheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001 Mar. 27(3):261-2. [Medline].

  4. Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve. 2003 Jun. 27(6):646-61. [Medline].

  5. Ohto T, Iwasaki N, Fujiwara J, et al. The evaluation of autonomic nervous function in a patient with hereditary sensory and autonomic neuropathy type IV with novel mutations of the TRKA gene. Neuropediatrics. 2004 Oct. 35(5):274-8. [Medline].

  6. Einarsdottir E, Carlsson A, Minde J, et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum Mol Genet. 2004 Apr 15. 13(8):799-805. [Medline].

  7. Low PA. Clinical autonomic disorders: evaluation and management. 2nd ed. New York: Lippincott Raven; 1997.

  8. Low PA, Dyck PJ, Lambert EH, et al. Acute panautonomic neuropathy. Ann Neurol. 1983 Apr. 13(4):412-7. [Medline].

  9. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000 Sep 21. 343(12):847-55. [Medline].

  10. Stewart JD, Low PA, Fealey RD. Distal small fiber neuropathy: results of tests of sweating and autonomic cardiovascular reflexes. Muscle Nerve. 1992 Jun. 15(6):661-5. [Medline].

  11. Emond D, Lebel M. Orthostatic hypotension and Holmes-Adie syndrome. Usefulness of the Valsalva ratio in the evaluation of baroreceptor dysfunction. J Hum Hypertens. 2002 Sep. 16(9):661-2. [Medline].

  12. Nolano M, Provitera V, Perretti A, Stancanelli A, Saltalamacchia AM, Donadio V, et al. Ross syndrome: a rare or a misknown disorder of thermoregulation? A skin innervation study on 12 subjects. Brain. 2006 Aug. 129:2119-31. [Medline].

  13. Low PA, Fealey RD, Sheps SG, Su WP, Trautmann JC, Kuntz NL. Chronic idiopathic anhidrosis. Ann Neurol. 1985 Sep. 18(3):344-8. [Medline].

  14. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007 Oct. 36(4):411-23. [Medline].

  15. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983 Oct. 58(10):665-83. [Medline].

  16. Low PA, Novak V, Spies JM, et al. Cerebrovascular regulation in the postural orthostatic tachycardia syndrome (POTS). Am J Med Sci. 1999 Feb. 317(2):124-33. [Medline].

  17. Novak V, Novak P, Opfer-Gehrking TL, et al. Clinical and laboratory indices that enhance the diagnosis of postural tachycardia syndrome. Mayo Clin Proc. 1998 Dec. 73(12):1141-50. [Medline].

  18. Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol. 1999 Apr. 9(2):369-91. [Medline].

  19. Vinik AI, Freeman R, Erbas T. Diabetic autonomic neuropathy. Semin Neurol. 2003 Dec. 23(4):365-72. [Medline].

  20. Clements RS Jr, Flint MA. Coping with autonomic neuropathy. J Diabet Complications. 1988 Jul-Sep. 2(3):130-2. [Medline].

  21. Supriya Simon A, Dinesh Roy D, Jayapal V, Vijayakumar T. Somatic DNA damages in cardiovascular autonomic neuropathy. Indian J Clin Biochem. 2011 Jan. 26(1):50-6. [Medline]. [Full Text].

  22. Semra YK, Wang M, Peat NJ, et al. Selective susceptibility of different populations of sympathetic neurons to diabetic neuropathy in vivo is reflected by increased vulnerability to oxidative stress in vitro. Neurosci Lett. 2006 Oct 30. 407(3):199-204. [Medline].

  23. Zochodne DW. The autonomic nervous system in peripheral neuropathies. Handbook of Clinical Neurology. 2000. 75(31):681-712.

  24. Maheshwari A, Thomas A, Thuluvath PJ. Patients with autonomic neuropathy are more likely to develop hepatic encephalopathy. Dig Dis Sci. 2004 Oct. 49(10):1584-8. [Medline].

  25. Beitzke M, Pfister P, Fortin J, Skrabal F. Autonomic dysfunction and hemodynamics in vitamin B12 deficiency. Auton Neurosci. 2002 Apr 18. 97(1):45-54. [Medline].

  26. Koike H, Sobue G. Alcoholic neuropathy. Curr Opin Neurol. 2006 Oct. 19(5):481-6. [Medline].

  27. Duray PH. Histopathology of clinical phases of human Lyme disease. Rheum Dis Clin North Am. 1989 Nov. 15(4):691-710. [Medline].

  28. Glück T, Degenhardt E, Schölmerich J, Lang B, Grossmann J, Straub RH. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res. 2000 Feb. 10(1):17-22. [Medline].

  29. Cohen JA, Laudenslager M. Autonomic nervous system involvement in patients with human immunodeficiency virus infection. Neurology. 1989 Aug. 39(8):1111-2. [Medline].

  30. Fernandez A, Hontebeyrie M, Said G. Autonomic neuropathy and immunological abnormalities in Chagas' disease. Clin Auton Res. 1992 Dec. 2(6):409-12. [Medline].

  31. Pentreath VW. Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 19 May 1994. Trypanosomiasis and the nervous system. Pathology and immunology. Trans R Soc Trop Med Hyg. 1995 Jan-Feb. 89(1):9-15. [Medline].

  32. Pickett JB 3rd. AAEE case report #16: Botulism. Muscle Nerve. 1988 Dec. 11(12):1201-5. [Medline].

  33. Idiaquez J. Autonomic dysfunction in diphtheritic neuropathy. J Neurol Neurosurg Psychiatry. 1992 Feb. 55(2):159-61. [Medline].

  34. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev. 2008 Sep. 79(3):242-53. [Medline].

  35. Kyriakidis MK, Noutsis CG, Robinson-Kyriakidis CA, Venetsianos PJ, Vyssoulis GP, Toutouzas PC, et al. Autonomic neuropathy in leprosy. Int J Lepr Other Mycobact Dis. 1983 Sep. 51(3):331-5. [Medline].

  36. Gibbons CH, Freeman R. Autonomic neuropathy and coeliac disease. J Neurol Neurosurg Psychiatry. 2005 Apr. 76(4):579-81. [Medline].

  37. Tursi A, Giorgetti GM, Iani C. Peripheral Neurological Disturbances, Autonomic Dysfunction, and Antineuronal Antibodies in Adult Celiac Disease Before and After a Gluten-Free Diet. Dig Dis Sci. 2006 Sep 12; [Epub ahead of print]. [Medline].

  38. Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, et al. Peripheral neuropathy associated with primary Sjögren's syndrome. J Neurol Neurosurg Psychiatry. 1994 Aug. 57(8):983-6. [Medline].

  39. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve. 1994 Oct. 17(10):1145-55. [Medline].

  40. Panegyres PK, Mastaglia FL. Guillain-Barre syndrome with involvement of the central and autonomic nervous systems. Med J Aust. 1989 Jun 5. 150(11):655-9. [Medline].

  41. O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology. 1998 Jan. 50(1):88-93. [Medline].

  42. Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002 Jun. 249(6):745-53. [Medline].

  43. Zenone T. [Autoimmunity and cancer: paraneoplastic neurological syndromes associated with small cell cancer]. Bull Cancer. 1992. 79(9):837-53. [Medline].

  44. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001 Feb. 49(2):146-54. [Medline].

  45. Straub RH, Antoniou E, Zeuner M, et al. Association of autonomic nervous hyperreflexia and systemic inflammation in patients with Crohn's disease and ulcerative colitis. J Neuroimmunol. 1997 Dec. 80(1-2):149-57. [Medline].

  46. Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006 Aug 15. 114(7):630-6. [Medline].

  47. Suarez GA, Opfer-Gehrking TL, Offord KP, et al. The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. Neurology. 1999 Feb. 52(3):523-8. [Medline].

  48. Watkins PJ. Diabetic diarrhea, gastroparesis, and gustatory sweating. Dyck PJ, Thomas PK, Asbury AK, et al, eds. Diabetic Neuropathy. Philadelphia: WB Saunders Co; 1987. 199-200.

  49. Bharucha AE, Camilleri M, Low PA, Zinsmeister AR. Autonomic dysfunction in gastrointestinal motility disorders. Gut. 1993 Mar. 34(3):397-401. [Medline].

  50. Törnblom H. Treatment of gastrointestinal autonomic neuropathy. Diabetologia. 2016 Mar. 59 (3):409-13. [Medline].

  51. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009 Jan 13. 72(2):177-84. [Medline].

  52. Foss CH, Vestbo E, Frøland A, Gjessing HJ, Mogensen CE, Damsgaard EM. Autonomic neuropathy in nondiabetic offspring of type 2 diabetic subjects is associated with urinary albumin excretion rate and 24-h ambulatory blood pressure: the Fredericia Study. Diabetes. 2001 Mar. 50(3):630-6. [Medline].

  53. Fealey RD. Thermoregulatory sweat test. Low PA, ed. Clinical Autonomic Disorders: Evaluation and Management. 2nd ed. Philadelphia: Lippincott-Raven; 1997. 245-57.

  54. Yarnitsky D, Sprecher E. Thermal testing: normative data and repeatability for various test algorithms. J Neurol Sci. 1994 Aug. 125(1):39-45. [Medline].

  55. Davies DR, Smith SE. Pupil abnormality in amyloidosis with autonomic neuropathy. J Neurol Neurosurg Psychiatry. 1999 Dec. 67(6):819-22. [Medline].

  56. Gibbons CH, Illigens BM, Centi J, Freeman R. QDIRT: quantitative direct and indirect test of sudomotor function. Neurology. 2008 Jun 10. 70(24):2299-304. [Medline].

  57. Madersbacher HG. Neurogenic bladder dysfunction. Curr Opin Urol. 1999 Jul. 9(4):303-7. [Medline].

  58. Ascaso JF, Herreros B, Sanchiz V, et al. Oesophageal motility disorders in type 1 diabetes mellitus and their relation to cardiovascular autonomic neuropathy. Neurogastroenterol Motil. 2006. 18(9):813-822. [Medline].

  59. Bissinger A, Grycewicz T, Grabowicz W, Lubinski A. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci. 2011 Oct. 7(5):806-12. [Medline]. [Full Text].

  60. Pavy-Le Traon A, Fontaine S, Tap G, Guidolin B, Senard JM, Hanaire H. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res. 2010 Jun. 20(3):153-60. [Medline].

  61. Ohlsson B, Melander O, Thorsson O, et al. Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis. Diabetologia. 2006 Sep. 49(9):2010-4. [Medline].

  62. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul. 131:1912-25. [Medline].

  63. Singer W, Spies JM, McArthur J, et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology. 2004 Feb 24. 62(4):612-8. [Medline].

  64. Nolano M, Provitera V, Crisci C, et al. Quantification of myelinated endings and mechanoreceptors in human digital skin. Ann Neurol. 2003 Aug. 54(2):197-205. [Medline].

  65. Nolano M, Crisci C, Santoro L, et al. Absent innervation of skin and sweat glands in congenital insensitivity to pain with anhidrosis. Clin Neurophysiol. 2000 Sep. 111(9):1596-601. [Medline].

  66. Klein CM, Vernino S, Lennon VA, et al. The spectrum of autoimmune autonomic neuropathies. Ann Neurol. 2003 Jun. 53(6):752-8. [Medline].

  67. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993 Aug. 68(8):748-52. [Medline].

  68. Jordan J, Shannon JR, Black BK, et al. The pressor response to water drinking in humans : a sympathetic reflex?. Circulation. 2000 Feb 8. 101(5):504-9. [Medline].

  69. van Lieshout JJ, ten Harkel AD, Wieling W. Physical manoeuvres for combating orthostatic dizziness in autonomic failure. Lancet. 1992 Apr 11. 339(8798):897-8. [Medline].

  70. Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007 Mar. 82(3):308-13. [Medline].

  71. Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res. 2008 Mar. 18 Suppl 1:14-8. [Medline].

  72. Low PA. Autonomic neuropathies. Curr Opin Neurol. 1998 Oct. 11(5):531-7. [Medline].

  73. Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol. 2006 Oct. 23(5):476-81. [Medline].

  74. Grubb BP. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation. 2005 Jun 7. 111(22):2997-3006. [Medline].

  75. Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res. 2000 Feb. 10(1):29-33. [Medline].

  76. Winkler AS, Landau S, Watkins PJ. Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. Diabetes Care. 2001 Jun. 24(6):1121-3. [Medline].

  77. Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed). 1986 Aug 9. 293(6543):353-4. [Medline].

  78. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004 Jun. 102(3):177-93. [Medline].

  79. Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005 Oct 13. 353(15):1585-90. [Medline].

  80. Modoni A, Mirabella M, Madia F, Sanna T, Lanza G, Tonali PA, et al. Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy. Neurology. 2007 Jan 9. 68(2):161-2. [Medline].

  81. Shotton HR, Adams A, Lincoln J. Effect of aminoguanidine treatment on diabetes-induced changes in the myenteric plexus of rat ileum. Auton Neurosci. 2006 Sep 18 [Epub ahead of print]. [Medline].

  82. Klein CM. Evaluation and management of autonomic nervous system disorders. Semin Neurol. 2008 Apr. 28(2):195-204. [Medline].

  83. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009. 10(2):87-102. [Medline].

  84. Monteiro E, Perdigoto R, Furtado AL. Liver transplantation for familial amyloid polyneuropathy. Hepatogastroenterology. 1998 Sep-Oct. 45(23):1375-80. [Medline].

  85. Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci. 1999 Dec 1. 171(1):19-23. [Medline].

  86. Antonelli Incalzi R, Fuso L, Pitocco D, et al. Decline of neuroadrenergic bronchial innervation and respiratory function in type 1 diabetes mellitus: a longitudinal study. Diabetes Metab Res Rev. 2006 Oct 2. [Medline].

  87. Dawkins JL, Hulme DJ, Brahmbhatt SB, et al. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet. 2001 Mar. 27(3):309-12. [Medline].

  88. El-Atat FA, McFarlane SI, Sowers JR, Bigger JT. Sudden cardiac death in patients with diabetes. Curr Diab Rep. 2004 Jun. 4(3):187-93. [Medline].

  89. Holland NR, Crawford TO, Hauer P, et al. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol. 1998 Jul. 44(1):47-59. [Medline].

  90. Kamalakannan D, Baskar V, Singh BM. Severe and disabling diabetic autonomic neuropathy: a case report. J Diabetes Complications. 2004 Mar-Apr. 18(2):126-8. [Medline].

  91. Kudat H, Akkaya V, Sozen AB, et al. Heart rate variability in diabetes patients. J Int Med Res. 2006 May-Jun. 34(3):291-6. [Medline].

  92. Low PA, Caskey PE, Tuck RR, et al. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983 Nov. 14(5):573-80. [Medline].

  93. Lyu RK, Tang LM, Wu YR, Chen ST. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Nov. 26(5):669-72. [Medline].

  94. Toth C, Zochodne DW. Other autonomic neuropathies. Semin Neurol. 2003 Dec. 23(4):373-80. [Medline].

  95. Zochodne DW, Auer R, Fritzler MJ. Longstanding ataxic demyelinating polyneuronopathy with a novel autoantibody. Neurology. 2003 Jan 14. 60(1):127-9. [Medline].

 
Previous
Next
 
Table. Types of HSAN
HSAN Mode of Inheritance Onset Symptoms Signs
Type I Autosomal dominant, point mutations in SPT, 9q22.1-9q22.3 Second decade of life Distal lower-limb involvement, ulceration of the feet, particularly the soles Low sensory action potential amplitude
Type II, Morvan disease Autosomal recessive Congenital onset Pansensory loss of upper and lower limbs, also trunk and forehead; early ulcers Loss of myelinated and unmyelinated fibers
Type III, Riley-Day syndrome or familial dysautonomia) Autosomal recessive, 9q31 Childhood onset, predominantly Ashkenazi Jews Pallor in infancy, irregularities in temperature and blood pressure; Difficulties in eating and swallowing Absence of unmyelinated fibers
Type IV Autosomal recessive, 1q21-1q22 Congenital onset Widespread anhidrosis, lost sense of pain, mental retardation Loss of myelinated and small unmyelinated fibers
Type V Autosomal recessive Congenital onset Pain insensitivity in extremities Not applicable
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.